Qure.ai's AI-driven chest X-ray solution for enhanced lung nodule detection gets USFDA clearance

Medical imaging solutions provider Qure.ai on Wednesday said it has received clearance from US health regulator for its artificial intelligence-enabled X-ray for detection of lung nodules.

Qure's chest X-ray-based qXR-LN uses artificial intelligence (AI)to identify and localize lung nodules thereby helping in identifying potentially malignant pulmonary nodules, thus boosting the fight against lung cancer, the company said in a statement.

This also marks the 6th USFDA (United States Food and Drug Administration) clearance for Qure's chest X-ray based solutions, the company said.

The qXR for lung nodule is a cutting-edge detection software designed to identify and highlight regions indicative of suspected pulmonary nodules ranging from 6 to 30 mm in size.

Prashant Warier, Co-Founder and CEO of Qure.ai, said the company has already deployed and implemented this solution globally, and the USFDA clearance ''marks yet another ground-breaking leap in our pioneering efforts to combat lung cancer''. ''Our heightened emphasis on the North American marketplace solidifies our commitment to making a meaningful impact in the fight against this deadly disease and underscores our dedication to advancing healthcare through innovation, providing a transformative solution enhancing the early detection of cancer and ultimately improving patient outcomes,'' Warier said.